John Craig Venter | |
---|---|
Born | Salt Lake City, Utah, U.S. | October 14, 1946
Alma mater | University of California, San Diego |
Occupation | Biologist |
Awards | Gairdner Award (2002) Nierenberg Prize (2007) Kistler Prize (2008) ENI award (2008) Medal of Science (2008) Dickson Prize (2011) Leeuwenhoek Medal Edogawa NICHE Prize (2020) |
Scientific career | |
Fields | |
Institutions | |
Website | www |
John Craig Venter (born October 14, 1946) is an American scientist. He is known for leading one of the first draft sequences of the human genome [1] [2] and led the first team to transfect a cell with a synthetic chromosome. [3] [4] Venter founded Celera Genomics, the Institute for Genomic Research (TIGR) and the J. Craig Venter Institute (JCVI). He was the co-founder of Human Longevity Inc. and Synthetic Genomics. He was listed on Time magazine's 2007 and 2008 Time 100 list of the most influential people in the world. In 2010, the British magazine New Statesman listed Craig Venter at 14th in the list of "The World's 50 Most Influential Figures 2010". [5] In 2012, Venter was honored with Dan David Prize for his contribution to genome research. [6] He was elected to the American Philosophical Society in 2013. [7] He is a member of the USA Science and Engineering Festival's advisory board. [8]
Venter was born in Salt Lake City, Utah, the son of Elisabeth and John Venter. [9] [10] : 14 His family moved to Millbrae, California during his childhood. [11] In his youth, he did not take his education seriously, preferring to spend his time on the water in boats or surfing. [10] : 1–20 According to his biography, A Life Decoded, he was said never to be a terribly engaged student, having Cs and Ds on his eighth-grade report cards. [10] : 1–20 Venter considered that his behavior in his adolescence was indicative of attention deficit hyperactivity disorder (ADHD), and later found ADHD-linked genetic variants in his own DNA. [12] He graduated from Mills High School. His father died suddenly at age 59 from cardiac arrest, giving him a lifelong awareness of his own mortality. He quotes a saying: "If you want immortality, do something meaningful with your life." [13]
Although he opposed the Vietnam War, [14] Venter was drafted and enlisted in the United States Navy where he worked as a hospital corpsman in the intensive-care ward of a field hospital. [15] He served from 1967 to 1968 at the Naval Support Activity Danang in Vietnam. While in Vietnam, he attempted suicide by swimming out to sea, but changed his mind more than a mile out. [16] Being confronted with severely injured and dying marines on a daily basis instilled in him a desire to study medicine, [17] although he later switched to biomedical research.
Venter began his college education in 1969 at a community college, College of San Mateo in California, and later transferred to the University of California, San Diego, where he studied under biochemist Nathan O. Kaplan. He received a Bachelor of Science in biochemistry in 1972 and a Doctor of Philosophy in physiology and pharmacology in 1975 from UCSD. [18] [19]
After working as an associate professor, and later as full professor, at the State University of New York at Buffalo, he joined the National Institutes of Health in 1984.
While an employee of the NIH, Venter learned how to identify mRNA and began to learn more about those expressed in the human brain. The short cDNA sequence fragments Venter discovered by automated DNA sequencing, he named expressed sequence tags, or ESTs. The NIH Office of Technology Transfer decided to file a patent on the ESTs discovered by Venter. patent the genes identified based on studies of mRNA expression in the human brain. When Venter disclosed the NIH strategy during a Congressional hearing, a firestorm of controversy erupted. [20] The NIH later stopped the effort and abandoned the patent applications it had filed, following public outcry. [21]
Venter was passionate about the power of genomics to transform healthcare radically. Venter believed that shotgun sequencing was the fastest and most effective way to get useful human genome data. [22] The method was rejected by the Human Genome Project however, since some geneticists felt it would not be accurate enough for a genome as complicated as that of humans, that it would be logistically more difficult, and that it would cost significantly more. [23] [24]
Venter viewed the slow pace of progress in the Human Genome project as an opportunity to continue his interest in trying his shotgun sequencing method to speed up the human genome sequencing so when he was offered funding from a DNA sequencing company to start Celera Genomics. [25] The company planned to profit from their work by creating genomic data to which users could subscribe for a fee. The goal consequently put pressure on the public genome program and spurred several groups to redouble their efforts to produce the full sequence. Venter's effort won him renown as he and his team at Celera Corporation shared credit for sequencing the first draft human genome with the publicly funded Human Genome Project. [26]
In 2000, Venter and Francis Collins of the National Institutes of Health and U.S. Public Genome Project jointly made the announcement of the mapping of the human genome, a full three years ahead of the expected end of the Public Genome Program. The announcement was made along with U.S. President Bill Clinton, and UK Prime Minister Tony Blair. [27] Venter and Collins thus shared an award for "Biography of the Year" from A&E Network. [28] On February 15, 2001, the Human Genome Project consortium published the first Human Genome in the journal Nature , followed one day later by a Celera publication in Science . [29] [30] Despite some claims that shotgun sequencing was in some ways less accurate than the clone-by-clone method chosen by the Human Genome Project, [31] the technique became widely accepted by the scientific community.
Venter was fired by Celera in early 2002. [32] According to his biography, Venter was fired because of a conflict with the main investor, Tony White, specifically barring him from attending the White House ceremony celebrating the achievement of sequencing the human genome.
The Global Ocean Sampling Expedition (GOS) is an ocean exploration genome project with the goal of assessing the genetic diversity in marine microbial communities and to understand their role in nature's fundamental processes. Begun as a Sargasso Sea pilot sampling project in August 2003, the full Expedition was announced by Venter on March 4, 2004. The project, which used Venter's personal yacht, Sorcerer II, started in Halifax, Canada, circumnavigated the globe and returned to the U.S. in January 2006. [33]
In June 2005, Venter co-founded Synthetic Genomics, a firm dedicated to using modified microorganisms to produce clean fuels and biochemicals. In July 2009, ExxonMobil announced a $600 million collaboration with Synthetic Genomics to research and develop next-generation biofuels. [34] Venter continues to work on the creation of engineered diatomic microalgae for the production of biofuels. [35] [36] [37]
Venter is seeking to patent the first partially synthetic species possibly to be named Mycoplasma laboratorium . [38] There is speculation that this line of research could lead to producing bacteria that have been engineered to perform specific reactions, for example, produce fuels, make medicines, combat global warming, and so on. [39]
In May 2010, a team of scientists led by Venter became the first to create successfully what was described as "synthetic life". [40] [41] This was done by synthesizing a very long DNA molecule containing an entire bacterium genome, and introducing this into another cell, analogous to the accomplishment of Eckard Wimmer's group, who synthesized and ligated an RNA virus genome and "booted" it in cell lysate. [42] The single-celled organism contains four "watermarks" [43] written into its DNA to identify it as synthetic and to help trace its descendants. The watermarks include
On March 25, 2016, Venter reported the creation of Syn 3.0, a synthetic genome having the fewest genes of any freely living organism (473 genes). Their aim was to strip away all nonessential genes, leaving only the minimal set necessary to support life. This stripped-down, fast reproducing cell is expected to be a valuable tool for researchers in the field. [45]
In August 2018, Venter retired as chairman of the board, saying he wanted to focus on his work at the J. Craig Venter Institute. He will remain as a scientific advisor to the board. [46]
In 2006 Venter founded the J. Craig Venter Institute (JCVI), a nonprofit which conducts research in synthetic biology. It has facilities in La Jolla and in Rockville, Maryland and employs over 200 people.
In April 2022 Venter sold the La Jolla JCVI facility to the University of California, San Diego for $25 million. Venter will continue to lead a separate nonprofit research group, also known as the J. Craig Venter Institute, and stressed that he is not retiring. The Venter Institute has out grown its current building with multiple new facility hires and will be moving into new space in 2025. [13]
On September 4, 2007, a team led by Sam Levy published one of the first genomes of an individual human—Venter's own DNA sequence. [47] Some of the sequences in Venter's genome are associated with wet earwax, [48] increased risk of antisocial behavior, Alzheimer's and cardiovascular diseases. [10]
The Human Reference Genome Browser is a web application for the navigation and analysis of Venter's recently published genome. The HuRef database consists of approximately 32 million DNA reads sequenced using microfluidic Sanger sequencing, assembled into 4,528 scaffolds and 4.1 million DNA variations identified by genome analysis. These variants include single-nucleotide polymorphisms (SNPs), block substitutions, short and large indels, and structural variations like insertions, deletions, inversions and copy number changes.
The browser enables scientists to navigate the HuRef genome assembly and sequence variations, and to compare it with the NCBI human build 36 assembly in the context of the NCBI and Ensembl annotations. The browser provides a comparative view between NCBI and HuRef consensus sequences, the sequence multi-alignment of the HuRef assembly, Ensembl and dbSNP annotations, HuRef variants, and the underlying variant evidence and functional analysis. The interface also represents the haplotype blocks from which diploid genome sequence can be inferred and the relation of variants to gene annotations. The display of variants and gene annotations are linked to external public resources including dbSNP, Ensembl, Online Mendelian Inheritance in Man (OMIM) and Gene Ontology (GO).
Users can search the HuRef genome using HUGO gene names, Ensembl and dbSNP identifiers, HuRef contig or scaffold locations, or NCBI chromosome locations. Users can then easily and quickly browse any genomic region via the simple and intuitive pan and zoom controls; furthermore, data relevant to specific loci can be exported for further analysis.
On March 4, 2014, Venter and co-founders Peter Diamandis and Robert Hariri announced the formation of Human Longevity, Inc., a company focused on extending the healthy, "high performance" human lifespan. [49] [50] At the time of the announcement the company had already raised $70 million in venture financing, which was expected to last 18 months. [49] [50] Venter served as the chairman and chief executive officer (CEO) until May 2018, when he retired. The company said that it plans to sequence 40,000 genomes per year, with an initial focus on cancer genomes and the genomes of cancer patients. [49]
Human Longevity filed a lawsuit in 2018 against Venter, accusing him of stealing trade secrets. Allegations were made stating that Venter had departed with his company computer that contained valuable information that could be used to start a competing business. [51] The lawsuit was ultimately dismissed by a California judge on the basis that Human Longevity were unable to present a case that met the legal threshold required for a company, or individual, to sue when its trade secrets have been stolen. [52]
Human Longevity's mission is to extend healthy human lifespan by the use of high-resolution big data diagnostics from genomics, metabolomics, microbiomics, and proteomics, and the use of stem cell therapy. [53]
Venter is the author of three books, the first of which is an autobiography titled A Life Decoded. [10] In Venter's second book, Life at the Speed of Light, he announced his theory that this is the generation in which there appears to be a dovetailing of the two previously diverse fields of science represented by computer programming and the genetic programming of life by DNA sequencing. [54] He was applauded for his position on this by futurist Ray Kurzweil. Venter's most recent book, co-authored by David Ewing Duncan, The Voyage of Sorcerer II: The Expedition that Unlocked the Secrets of the Ocean’s Microbiome, [55] details the Global Ocean Sampling Expedition, spanning a 15-year period during which microbes from the world's oceans were collected and their DNA sequenced.
After a 12-year marriage to Barbara Rae-Venter, [56] [57] with whom he had a son, Christopher, he married Claire M. Fraser [58] [19] remaining married to her until 2005. [59] In late 2008 he married Heather Kowalski. [60] They live in the La Jolla neighborhood of San Diego, CA. [60] Venter is an atheist. [61]
Venter was 75 when he sold his main research building to UCSD in 2022. The institute had out grown the space and will be moving to a new facility in 2025. The Venter Institute campus in Rockville MD also continues to expand. He said he has no intention of retiring. [13] He has a home in La Jolla and a ranch in Borrego Springs, California, as well as homes in two small towns in Maine. He indulges in two passions: sailing and flying a Cirrus 22T plane, which he calls "the ultimate freedom". [13]
Venter has been the subject of articles in several magazines, including Wired , [62] The Economist , [63] Australian science magazine Cosmos , [64] [65] and The Atlantic . [66]
Venter appears in the two-hour 2001 NOVA special, "Cracking the code of life". [67] [68]
On May 16, 2004, Venter gave the commencement speech at Boston University. [69]
On December 4, 2007, Venter gave the Dimbleby lecture for the BBC in London. [70]
Venter gave the Distinguished Public Lecture during the 2007 Michaelmas Term at the James Martin 21st Century School at Oxford University. Its title was "Genomics – From humans to the environment". [71] [72]
Venter delivered the 2008 convocation speech for Faculty of Science honours and specialization students at the University of Alberta. [73]
In February 2008, he gave a speech about his current work at the TED conference. [74]
Venter was featured in Time magazine's "The Top 10 Everything of 2008" article. Number three in 2008's Top 10 Scientific Discoveries was a piece outlining his work stitching together the 582,000 base pairs necessary to invent the genetic information for a whole new bacterium. [75]
On May 20, 2010, Venter announced the creation of first self-replicating semi-synthetic bacterial cell. [76]
In the June 2011 issue of Men's Journal , Venter was featured as the "Survival Skills" celebrity of the month. He shared various anecdotes and advice, including stories of his time in Vietnam, as well as mentioning a bout with melanoma on his back, which subsequently resulted in his "giving a pound of flesh" to surgery. [77]
In May 2011, Venter was the commencement speaker at the 157th commencement of Syracuse University. [78] [79]
In May 2017, Venter was the guest of honor and keynote speaker at the inauguration ceremony of the Center for Systems Biology Dresden. [80]
Venter has authored over 200 publications in scientific journals. [97]
The human genome is a complete set of nucleic acid sequences for humans, encoded as the DNA within each of the 24 distinct chromosomes in the cell nucleus. A small DNA molecule is found within individual mitochondria. These are usually treated separately as the nuclear genome and the mitochondrial genome. Human genomes include both protein-coding DNA sequences and various types of DNA that does not encode proteins. The latter is a diverse category that includes DNA coding for non-translated RNA, such as that for ribosomal RNA, transfer RNA, ribozymes, small nuclear RNAs, and several types of regulatory RNAs. It also includes promoters and their associated gene-regulatory elements, DNA playing structural and replicatory roles, such as scaffolding regions, telomeres, centromeres, and origins of replication, plus large numbers of transposable elements, inserted viral DNA, non-functional pseudogenes and simple, highly repetitive sequences. Introns make up a large percentage of non-coding DNA. Some of this non-coding DNA is non-functional junk DNA, such as pseudogenes, but there is no firm consensus on the total amount of junk DNA.
Genomics is an interdisciplinary field of molecular biology focusing on the structure, function, evolution, mapping, and editing of genomes. A genome is an organism's complete set of DNA, including all of its genes as well as its hierarchical, three-dimensional structural configuration. In contrast to genetics, which refers to the study of individual genes and their roles in inheritance, genomics aims at the collective characterization and quantification of all of an organism's genes, their interrelations and influence on the organism. Genes may direct the production of proteins with the assistance of enzymes and messenger molecules. In turn, proteins make up body structures such as organs and tissues as well as control chemical reactions and carry signals between cells. Genomics also involves the sequencing and analysis of genomes through uses of high throughput DNA sequencing and bioinformatics to assemble and analyze the function and structure of entire genomes. Advances in genomics have triggered a revolution in discovery-based research and systems biology to facilitate understanding of even the most complex biological systems such as the brain.
Celera Corporation is a subsidiary of Quest Diagnostics which focuses on genetic sequencing and related technologies. It was founded in 1998 as a business unit of Applera, spun off into an independent company in 2008, and finally acquired by Quest Diagnostics in 2011.
Eric Steven Lander is an American mathematician and geneticist who is a professor of biology at the Massachusetts Institute of Technology (MIT), and a professor of systems biology at Harvard Medical School. Eric Lander is founding director emeritus of the Broad Institute of MIT and Harvard.
DNA sequencing is the process of determining the nucleic acid sequence – the order of nucleotides in DNA. It includes any method or technology that is used to determine the order of the four bases: adenine, guanine, cytosine, and thymine. The advent of rapid DNA sequencing methods has greatly accelerated biological and medical research and discovery.
The J. Craig Venter Institute (JCVI) is a non-profit genomics research institute founded by J. Craig Venter, Ph.D. in October 2006. The institute was the result of consolidating four organizations: the Center for the Advancement of Genomics, The Institute for Genomic Research (TIGR), the Institute for Biological Energy Alternatives, and the J. Craig Venter Science Foundation Joint Technology Center. It has facilities in Rockville, Maryland, and San Diego, California.
Hamilton Othanel Smith is an American microbiologist and Nobel laureate.
In September 2021, Synthetic Genomics Inc. (SGI), a private company located in La Jolla, California, changed its name to Viridos. The company is focused on the field of synthetic biology, especially harnessing photosynthesis with micro algae to create alternatives to fossil fuels. Viridos designs and builds biological systems to address global sustainability problems.
George McDonald Church is an American geneticist, molecular engineer, chemist, serial entrepreneur, and pioneer in personal genomics and synthetic biology. He is the Robert Winthrop Professor of Genetics at Harvard Medical School, Professor of Health Sciences and Technology at Harvard University and Massachusetts Institute of Technology, and a founding member of the Wyss Institute for Biologically Inspired Engineering at Harvard University.
The Human Genome Project (HGP) was an international scientific research project with the goal of determining the base pairs that make up human DNA, and of identifying, mapping and sequencing all of the genes of the human genome from both a physical and a functional standpoint. It started in 1990 and was completed in 2003. It remains the world's largest collaborative biological project. Planning for the project began in 1984 by the US government, and it officially launched in 1990. It was declared complete on April 14, 2003, and included about 92% of the genome. Level "complete genome" was achieved in May 2021, with only 0.3% of the bases covered by potential issues. The final gapless assembly was finished in January 2022.
The Neanderthal genome project is an effort of a group of scientists to sequence the Neanderthal genome, founded in July 2006.
The Archon Genomics X PRIZE presented by Express Scripts for Genomics, the second X Prize offered by the X Prize Foundation, based in Playa Vista, California, was announced on October 4, 2006 stating that the prize of "$10 million will be awarded to the first team to rapidly, accurately and economically sequence 100 whole human genomes to an unprecedented level of accuracy." The 30 day evaluation phase of the competition to begin on September 5, 2013, was canceled August 22, 2013 and this cancellation was debated on March 27, 2014.
Synthetic genomics is a nascent field of synthetic biology that uses aspects of genetic modification on pre-existing life forms, or artificial gene synthesis to create new DNA or entire lifeforms.
Applied Biosystems is one of various brands under the Life Technologies brand of Thermo Fisher Scientific corporation. The brand is focused on integrated systems for genetic analysis, which include computerized machines and the consumables used within them.
Applera Corporation of Norwalk, Connecticut, at #874 on the 2007 Fortune 1000 list, was one of the largest international biotechnology companies based in the United States. It was the successor company to what was the Life Sciences Division of Perkin-Elmer Corporation. Applera was not publicly traded, but instead it consisted of two major groups which are publicly traded tracking stocks in the proteomics industrial sector. These two groups were the S&P 500 listed Applera Corp-Applied Biosystems Group of Foster City, California, and Applera Corp-Celera Genomics Group of Rockville, Maryland. In 2006, the company spun off the Celera Genomics group and changed its name from Applera to Applied Biosystems.
Mycoplasma laboratorium or Synthia refers to a synthetic strain of bacterium. The project to build the new bacterium has evolved since its inception. Initially the goal was to identify a minimal set of genes that are required to sustain life from the genome of Mycoplasma genitalium, and rebuild these genes synthetically to create a "new" organism. Mycoplasma genitalium was originally chosen as the basis for this project because at the time it had the smallest number of genes of all organisms analyzed. Later, the focus switched to Mycoplasma mycoides and took a more trial-and-error approach.
Whole genome sequencing (WGS) is the process of determining the entirety, or nearly the entirety, of the DNA sequence of an organism's genome at a single time. This entails sequencing all of an organism's chromosomal DNA as well as DNA contained in the mitochondria and, for plants, in the chloroplast.
The $1,000 genome refers to an era of predictive and personalized medicine during which the cost of fully sequencing an individual's genome (WGS) is roughly one thousand USD. It is also the title of a book by British science writer and founding editor of Nature Genetics, Kevin Davies. By late 2015, the cost to generate a high-quality "draft" whole human genome sequence was just below $1,500.
Synthetic virology is a branch of virology engaged in the study and engineering of synthetic man-made viruses. It is a multidisciplinary research field at the intersection of virology, synthetic biology, computational biology, and DNA nanotechnology, from which it borrows and integrates its concepts and methodologies. There is a wide range of applications for synthetic viral technology such as medical treatments, investigative tools, and reviving organisms.
Vineet Bafna is an Indian bioinformatician and professor of computer science and director of bioinformatics program at University of California, San Diego. He was elected a Fellow of the International Society for Computational Biology (ISCB) in 2019 for outstanding contributions to the fields of computational biology and bioinformatics. He has also been a member of the Research in Computational Molecular Biology (RECOMB) conference steering committee.
For many years I have been trying to make sense and meaning out of the lives I saw destroyed or maimed due to the government policies that involved us in the war in Vietnam.
The genome we published at Celera was a composite of five people. ... After leaving Celera in 2002, Venter announced that much of the genome that had been sequenced there was his own.